EcoDrugPlus

Histone Deacetylase 2

Ensembl ID : ENSNBRG00000011433
Gene Symbol: HDAC2
4 Cross references
209 Possible Orthologues:

Histone Deacetylase 3

Ensembl ID : ENSNBRG00000022356
Gene Symbol: HDAC3
4 Cross references
155 Possible Orthologues:

Histone Deacetylase 4-Like

Ensembl ID : ENSNBRG00000015261
Gene Symbol: LOC102791991
3 Cross references
202 Possible Orthologues:

Histone Deacetylase 5

Ensembl ID : ENSNBRG00000024303
Gene Symbol: HDAC5
3 Cross references
194 Possible Orthologues:

Histone Deacetylase 6

Ensembl ID : ENSNBRG00000008791
Gene Symbol: HDAC6
3 Cross references
180 Possible Orthologues:

Histone Deacetylase 7

Ensembl ID : ENSNBRG00000019373
Gene Symbol: HDAC7
3 Cross references
189 Possible Orthologues:

Histone Deacetylase 8-Like

Ensembl ID : ENSNBRG00000011887
Gene Symbol: LOC102785364
3 Cross references
205 Possible Orthologues:

Hydroxycarboxylic Acid Receptor 1

Ensembl ID : ENSNBRG00000008254
Gene Symbol: HCAR1
4 Cross references
233 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSNBRG00000010298
Gene Symbol: HCN4
3 Cross references
221 Possible Orthologues:

Hyperpolarization Activated Cyclic Nucleotide Gated Potassium Channel 4

Ensembl ID : ENSNBRG00000002641
Gene Symbol: HCN4
4 Cross references
212 Possible Orthologues:

Induced Myeloid Leukemia Cell Differentiation Protein Mcl-1 Homolog

Ensembl ID : ENSNBRG00000013968
Gene Symbol: LOC102788812
3 Cross references
211 Possible Orthologues:

Inhibitor Of Nuclear Factor Kappa-B Kinase Subunit Beta-Like

Ensembl ID : ENSNBRG00000019905
Gene Symbol: LOC102782918
3 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).